Last reviewed · How we verify
Lotrel (amlodipine/benazepril)
Lotrel combines a calcium channel blocker and an ACE inhibitor to lower blood pressure through two complementary pathways: relaxing blood vessel smooth muscle and reducing angiotensin II-mediated vasoconstriction.
Lotrel combines a calcium channel blocker and an ACE inhibitor to lower blood pressure through two complementary pathways: relaxing blood vessel smooth muscle and reducing angiotensin II-mediated vasoconstriction. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Lotrel (amlodipine/benazepril) |
|---|---|
| Sponsor | Abbott |
| Drug class | Calcium channel blocker / ACE inhibitor combination |
| Target | L-type calcium channels (amlodipine); Angiotensin-converting enzyme (benazepril) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Benazepril inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion. Together, these mechanisms provide additive antihypertensive effects.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Headache
- Dizziness
- Fatigue
- Peripheral edema
- Cough
- Palpitations
Key clinical trials
- Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets (PHASE1)
- Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions (PHASE1)
- Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions (PHASE1)
- Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg (PHASE1)
- Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg (PHASE1)
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (PHASE3)
- Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension (PHASE4)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lotrel (amlodipine/benazepril) CI brief — competitive landscape report
- Lotrel (amlodipine/benazepril) updates RSS · CI watch RSS
- Abbott portfolio CI